Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives

被引:24
|
作者
Flegg, Jennifer A. [1 ,2 ]
Guerin, Philippe J. [1 ,2 ]
Nosten, Francois [2 ,3 ,4 ]
Ashley, Elizabeth A. [2 ,3 ]
Phyo, Aung Pyae [3 ,4 ]
Dondorp, Arjen M. [2 ,3 ]
Fairhurst, Rick M. [5 ]
Socheat, Duong [6 ]
Borrmann, Steffen [7 ]
Bjorkman, Anders [8 ]
Martensson, Andreas [8 ,9 ]
Mayxay, Mayfong [10 ]
Newton, Paul N. [2 ,10 ]
Bethell, Delia [11 ]
Se, Youry [12 ]
Noedl, Harald [13 ]
Diakite, Mahamadou [14 ]
Djimde, Abdoulaye A. [14 ]
Hien, Tran T. [2 ,15 ]
White, Nicholas J. [2 ,3 ]
Stepniewska, Kasia [1 ,2 ]
机构
[1] Univ Oxford, WorldWide Antimalarial Resistance Network WWARN, Oxford, England
[2] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England
[3] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand
[4] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand
[5] NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA
[6] Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia
[7] Kenya Govt Med Res Ctr, Wellcome Trust Res Programme, Kilifi, Kenya
[8] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Stockholm, Sweden
[9] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden
[10] Mahosot Hosp, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit L, Microbiol Lab, Viangchan, Laos
[11] AFRIMS, Dept Immunol & Med, Bangkok, Thailand
[12] AFRIMS, Phnom Penh, Cambodia
[13] Med Univ Vienna, Inst Specif Prophylaxis & Trop Med, Vienna, Austria
[14] Univ Bamako, Malaria Res & Training Ctr, Bamako, Mali
[15] OUCRU, Ho Chi Minh City, Vietnam
来源
MALARIA JOURNAL | 2013年 / 12卷
关键词
Plasmodium falciparum; Malaria; Artemisinin resistance; Parasite clearance; Simulation; PARASITE CLEARANCE; MALARIA; ARTESUNATE; RESISTANCE; CAMBODIA;
D O I
10.1186/1475-2875-12-411
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The emergence of Plasmodium falciparum resistance to artemisinins in Southeast Asia threatens the control of malaria worldwide. The pharmacodynamic hallmark of artemisinin derivatives is rapid parasite clearance (a short parasite half-life), therefore, the in vivo phenotype of slow clearance defines the reduced susceptibility to the drug. Measurement of parasite counts every six hours during the first three days after treatment have been recommended to measure the parasite clearance half-life, but it remains unclear whether simpler sampling intervals and frequencies might also be sufficient to reliably estimate this parameter. Methods: A total of 2,746 parasite density-time profiles were selected from 13 clinical trials in Thailand, Cambodia, Mali, Vietnam, and Kenya. In these studies, parasite densities were measured every six hours until negative after treatment with an artemisinin derivative (alone or in combination with a partner drug). The WWARN Parasite Clearance Estimator (PCE) tool was used to estimate "reference" half-lives from these six-hourly measurements. The effect of four alternative sampling schedules on half-life estimation was investigated, and compared to the reference half-life (time zero, 6, 12, 24 (A1); zero, 6, 18, 24 (A2); zero, 12, 18, 24 (A3) or zero, 12, 24 (A4) hours and then every 12 hours). Statistical bootstrap methods were used to estimate the sampling distribution of half-lives for parasite populations with different geometric mean half-lives. A simulation study was performed to investigate a suite of 16 potential alternative schedules and half-life estimates generated by each of the schedules were compared to the "true" half-life. The candidate schedules in the simulation study included (among others) six-hourly sampling, schedule A1, schedule A4, and a convenience sampling schedule at six, seven, 24, 25, 48 and 49 hours. Results: The median (range) parasite half-life for all clinical studies combined was 3.1 (0.7-12.9) hours. Schedule A1 consistently performed the best, and schedule A4 the worst, both for the individual patient estimates and for the populations generated with the bootstrapping algorithm. In both cases, the differences between the reference and alternative schedules decreased as half-life increased. In the simulation study, 24-hourly sampling performed the worst, and six-hourly sampling the best. The simulation study confirmed that more dense parasite sampling schedules are required to accurately estimate half-life for profiles with short half-life (<= three hours) and/or low initial parasite density (<= 10,000 per mu L). Among schedules in the simulation study with six or fewer measurements in the first 48 hours, a schedule with measurements at times (time windows) of 0 (0-2), 6 (4-8), 12 (10-14), 24 (22-26), 36 (34-36) and 48 (46-50) hours, or at times 6, 7 (two samples in time window 5-8), 24, 25 (two samples during time 23-26), and 48, 49 (two samples during time 47-50) hours, until negative most accurately estimated the "true" half-life. For a given schedule, continuing sampling after two days had little effect on the estimation of half-life, provided that adequate sampling was performed in the first two days and the half-life was less than three hours. If the measured parasitaemia at two days exceeded 1,000 per mu L, continued sampling for at least once a day was needed for accurate half-life estimates. Conclusions: This study has revealed important insights on sampling schedules for accurate and reliable estimation of Plasmodium falciparum half-life following treatment with an artemisinin derivative (alone or in combination with a partner drug). Accurate measurement of short half-lives (rapid clearance) requires more dense sampling schedules (with more than twice daily sampling). A more intensive sampling schedule is, therefore, recommended in locations where P. falciparum susceptibility to artemisinins is not known and the necessary resources are available. Counting parasite density at six hours is important, and less frequent sampling is satisfactory for estimating long parasite half-lives in areas where artemisinin resistance is present.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials
    Wongsrichanalai, C
    Dung, NT
    Trung, TN
    Wimonwattrawatee, T
    Sookto, P
    Heppner, DG
    Kawamoto, F
    ACTA TROPICA, 1997, 63 (2-3) : 151 - 158
  • [22] Artemisinin derivatives for treatment of uncomplicated Plasmodium falciparum malaria in Sudan: too early for too much hope
    Hayder A. Giha
    Parasitology Research, 2010, 106 : 549 - 552
  • [23] Plasmodium falciparum malaria: Convergent evolutionary trajectories towards delayed clearance following artemisinin treatment
    Wilairat, Prapon
    Kuempornsin, Krittikorn
    Chookajorn, Thanat
    MEDICAL HYPOTHESES, 2016, 90 : 19 - 22
  • [24] Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy
    Silva, M.
    Ferreira, P. E.
    Otienoburu, S. D.
    Calcada, C.
    Ngasala, B.
    Bjorkman, A.
    Martensson, A.
    Gil, J. P.
    Veiga, M. I.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (07) : 1890 - 1893
  • [25] Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia
    Duru, Valentine
    Witkowski, Benoit
    Menard, Didier
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2016, 95 (06) : 1228 - 1238
  • [26] Plasmodium falciparum Genotype Diversity in Artemisinin Derivatives Treatment Failure Patients along the Thai-Myanmar Border
    Congpuong, Kanungnit
    Hoonchaiyapoom, Thirasak
    Inorn, Komnarin
    KOREAN JOURNAL OF PARASITOLOGY, 2014, 52 (06) : 631 - 637
  • [27] Differential Effects of Antimalarial Drugs on Parasite Clearance Rates Are Reflected by Plasmodium falciparum Ring Ratio
    Saidi, Alexuse M.
    Zhang, Bo
    Jiang, Melody
    Kawaza, Kondwani
    Musaya, Janelisa
    Taylor, Terrie
    Seydel, Karl
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (07):
  • [28] Assessing parasite clearance during uncomplicated Plasmodium falciparum infection treated with artesunate monotherapy in Suriname
    Vreden, Stephen G. S.
    Bansie, Rakesh D.
    Jitan, Jeetendra K.
    Adhin, Malti R.
    INFECTION AND DRUG RESISTANCE, 2016, 9 : 261 - 267
  • [29] Plasmodium falciparum sexual conversion rates can be affected by artemisinin-based treatment in naturally infected malaria patients
    Portugaliza, Harvie P.
    Natama, H. Magloire
    Guetens, Pieter
    Rovira-Vallbona, Eduard
    Some, Athanase M.
    Millogo, Aida
    Ouedraogo, D. Florence
    Valea, Innocent
    Sorgho, Hermann
    Tinto, Halidou
    Nguyen Van Hong
    Sitoe, Antonio
    Varo, Rosauro
    Bassat, Quique
    Cortes, Alfred
    Rosanas-Urgell, Anna
    EBIOMEDICINE, 2022, 83
  • [30] Prevalence and characterization of piperaquine, mefloquine and artemisinin derivatives triple-resistant Plasmodium falciparum in Cambodia
    Mairet-Khedim, Melissa
    Roesch, Camille
    Khim, Nimol
    Srun, Sreynet
    Bouillon, Anthony
    Kim, Saorin
    Ke, Sopheakvatey
    Kauy, Chhayleang
    Kloeung, Nimol
    Eam, Rotha
    Khean, Chanra
    Kul, Chanvong
    Chy, Sophy
    Leang, Rithea
    Ringwald, Pascal
    Barale, Jean-Christophe
    Witkowski, Benoit
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (02) : 411 - 417